Medidata and inVentiv Health announced a multi-year partnership to bring patient-centric technology and clinical trial expertise to the biopharmaceutical industry. The partnership will broaden the reach of Medidata’s electronic informed consent (eConsent) technology, Medidata Enroll.
Medidata recently acquired Mytrus, an eClinical technology company specializing in eConsent and virtual trials. inVentiv, an early adopter of eConsent technology, invested in Mytrus in 2013. inVentiv and Medidata will now partner to provide their joint customers with training, services and support around the use of the eConsent platform, Medidata Enroll.
“As clinical development evolves toward a more patient-centric, technologically-savvy model, the use of eConsent is becoming increasingly relevant,” said Rachel Stahler, Chief Information Officer, inVentiv Health. “By pairing Medidata’s industry-leading technology platform with inVentiv’s vast clinical trial and patient engagement capabilities, we can expedite study start-up and transform the trial process for patients and sites. This partnership reinforces our commitment to delivering better systems, rich data and actionable insights to accelerate our clients’ abilities to deliver important therapies to market.”
Electronic informed consent provides patients with clear, visually compelling information about trial participation in an easily accessible digital format. This process facilitates dialogue between physician and patient, and may increase patient engagement in a trial. Medidata Enroll also provides visualization and analytics for trial sponsors and monitors, and streamlines site workflow and data capture.